Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Phase 1
Recruiting
- Conditions
- Recurrent CancerRefractory CancerChildhood CancerChildhood Brain TumorChildhood Solid Tumor
- Interventions
- Drug: Paxalisib, Irinotecan, Temozolomide
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2025-02-21
- Target Recruit Count
- 82
- Registration Number
- NCT06208657
- Locations
- 🇦🇺
John Hunter Children's Hospital, Newcastle, New South Wales, Australia
🇦🇺Sydney Children's Hospital, Randwick, Sydney, New South Wales, Australia
🇦🇺The Children's Hospital at Westmead, Sydney, New South Wales, Australia
Precision Medicine for Every Child With Cancer
Recruiting
- Conditions
- Childhood Solid TumorChildhood LeukemiaRefractory CancerChildhood CancerChildhood Brain TumorRelapsed Cancer
- Interventions
- Genetic: Whole Genome SequencingGenetic: RNA seqGenetic: DNA MethylationGenetic: Targeted Panel SequencingOther: Liquid BiopsyGenetic: High Throughput Sequencing (in vitro)Genetic: Patient Derived Xenograft (PDX)(in vivo)
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2024-07-17
- Target Recruit Count
- 3500
- Registration Number
- NCT05504772
- Locations
- 🇦🇺
Perth Children's Hospital, Perth, Australia
🇦🇺Women's and Children's Hospital, Adelaide, Australia
🇦🇺Royal Children's Hospital, Melbourne, Australia
A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT
Phase 2
Terminated
- Conditions
- Rhabdoid TumorAtypical Teratoid/Rhabdoid TumorRecurrent Brain Tumor, ChildhoodMalignant Rhabdoid Tumor
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2025-02-24
- Target Recruit Count
- 25
- Registration Number
- NCT04897880
- Locations
- 🇦🇺
John Hunter Children's Hospital, New Lambton, New South Wales, Australia
🇺🇸The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, United States
🇦🇺Sydney Children's Hospital, Randwick, New South Wales, Australia
© Copyright 2025. All Rights Reserved by MedPath